- Triera Biosciences, a Zentek company, has launched contract research organization (CRO) services focused on aptamer discovery, biosensor development, and machine-learning classification.
- The offering is supported by an exclusive 20-year license from McMaster University and targets pharmaceutical, biotechnology, and diagnostics customers.
Triera Biosciences, a subsidiary of Zentek Ltd., has launched contract research organization (CRO) services focused on custom aptamer discovery, biosensor enablement, and machine-learning classification. The company said the new offering is designed to support pharmaceutical, biotechnology, and diagnostics companies that require molecular recognition technologies but lack in-house development capabilities.
The CRO services are supported by an exclusive 20-year license from McMaster University and combine aptamer discovery through SELEX, biosensor engineering, and optional machine-learning classification workflows. The company said the platform is intended to support applications across infectious disease detection, oncology, and therapeutic development programs.
The company also noted that the services will initially target customers across North America and Europe. According to the announcement, the model is designed to support organizations seeking specialized discovery capabilities without building internal infrastructure.
“The launch of Triera Biosciences’ CRO services represents an important step in the commercialization of our aptamer platform and provides a pathway to near-term revenue opportunities while continuing to advance internal programs.”
Greg Fenton, CEO of Zentek
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
